Synergy Pharmaceuticals Company Profile (NASDAQ:SGYP)

About Synergy Pharmaceuticals

Synergy Pharmaceuticals logoSynergy Pharmaceuticals Inc. (Synergy) is a biopharmaceutical company focused on the development and commercialization of gastrointestinal (GI) therapies. The Company's GI platform includes two lead product candidates: plecanatide and dolcanatide. It is engaged in the discovery, research and development involving uroguanylin analogs for the treatment of functional GI disorders and inflammatory bowel disease. Plecanatide is the Company's uroguanylin analog being evaluated for use as a once-daily tablet for two functional GI disorders, chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). Plecanatide is a 16-amino acid peptide that is structurally identical to uroguanylin with the exception of a single amino acid change. Dolcanatide is also its uroguanylin analog being explored for inflammatory bowel disease (IBD). Dolcanatide is designed to be an analog of uroguanylin with resistance to standard digestive breakdown by proteases in the intestine.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Other
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: SGYP
  • CUSIP: 87163930
Key Metrics:
  • Previous Close: $5.48
  • 50 Day Moving Average: $6.29
  • 200 Day Moving Average: $5.47
  • 52-Week Range: $2.50 - $7.15
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -11.18
  • P/E Growth: 0.00
  • Market Cap: $986.14M
  • Outstanding Shares: 179,953,000
  • Beta: 923.12
Profitability:
  • Return on Assets: -124.14%
Debt:
  • Debt-to-Equity Ratio: 6.31%
  • Current Ratio: 4.71%
  • Quick Ratio: 4.71%
Additional Links:
Companies Related to Synergy Pharmaceuticals:

Analyst Ratings

Consensus Ratings for Synergy Pharmaceuticals (NASDAQ:SGYP) (?)
Ratings Breakdown: 1 Hold Rating, 6 Buy Ratings
Consensus Rating:Buy (Score: 2.86)
Consensus Price Target: $11.50 (109.85% upside)

Analysts' Ratings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Show:
DateFirmActionRatingPrice TargetDetails
1/31/2017Oppenheimer Holdings, Inc.Reiterated RatingOutperform$10.00View Rating Details
1/28/2017Canaccord GenuityReiterated RatingBuy$13.00View Rating Details
1/27/2017HC WainwrightSet Price TargetBuy$18.00View Rating Details
1/26/2017BTIG ResearchReiterated RatingPositive$11.00View Rating Details
1/20/2017Rodman & RenshawBoost Price TargetBuy$17.00 -> $18.00View Rating Details
12/15/2016Roth CapitalReiterated RatingBuy$6.50View Rating Details
3/16/2016Citigroup Inc.Lower Price TargetNeutral$7.00 -> $4.00View Rating Details
6/18/2015Cantor FitzgeraldReiterated RatingBuy$8.50 -> $14.00View Rating Details
(Data available from 2/24/2015 forward)

Earnings

Earnings History for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/23/2017        
8/8/2016Q216($0.20)($0.23)ViewN/AView Earnings Details
5/10/2016Q1($0.23)($0.51)ViewN/AView Earnings Details
11/9/2015Q315($0.28)($0.23)ViewN/AView Earnings Details
8/10/2015Q215($0.28)($0.34)$102.00 millionViewN/AView Earnings Details
5/11/2015Q115($0.33)($0.28)ViewN/AView Earnings Details
3/16/2015($0.28)($0.32)ViewN/AView Earnings Details
11/10/2014($0.28)($0.24)ViewN/AView Earnings Details
8/11/2014($0.23)($0.28)ViewN/AView Earnings Details
5/13/2014Q114($0.23)($0.18)ViewN/AView Earnings Details
3/17/2014Q4 13($0.20)($0.22)ViewN/AView Earnings Details
11/12/2013Q3($0.17)($0.15)ViewN/AView Earnings Details
11/13/2012Q312($0.01)($0.15)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Synergy Pharmaceuticals (NASDAQ:SGYP)
Current Year EPS Consensus Estimate: $-1.05 EPS
Next Year EPS Consensus Estimate: $-0.49 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.19)($0.19)($0.19)
Q2 20161($0.25)($0.25)($0.25)
Q3 20161($0.25)($0.25)($0.25)
Q4 20162($0.20)($0.18)($0.19)
Q1 20171($0.16)($0.16)($0.16)
Q2 20171($0.14)($0.14)($0.14)
Q3 20171($0.14)($0.14)($0.14)
Q4 20171($0.12)($0.12)($0.12)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Synergy Pharmaceuticals (NASDAQ:SGYP)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Synergy Pharmaceuticals (NASDAQ:SGYP)
Insider Ownership Percentage: 3.60%
Institutional Ownership Percentage: 55.36%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/4/2016Paulson & Co. Inc.Major ShareholderSell140,000$4.24$593,600.00View SEC Filing  
9/28/2016Paulson & Co. Inc.Major ShareholderSell54,300$5.69$308,967.00View SEC Filing  
9/19/2016John P BrancaccioDirectorSell2,518$5.76$14,503.68View SEC Filing  
9/19/2016Paulson & Co. Inc.Major ShareholderSell3,473,713$5.61$19,487,529.93View SEC Filing  
9/14/2015Bernard DenoyerSVPSell10,000$7.50$75,000.00View SEC Filing  
9/11/2015Alan JoslynDirectorSell13,754$7.22$99,303.88View SEC Filing  
6/3/2014John P BrancaccioDirectorBuy3,500$4.12$14,420.00View SEC Filing  
5/27/2014Gary S JacobCEOBuy4,000$4.18$16,720.00View SEC Filing  
5/23/2014Bernard DenoyerSVPBuy2,500$3.89$9,725.00View SEC Filing  
5/23/2014Kunwar ShailubhaiInsiderBuy3,000$3.89$11,670.00View SEC Filing  
10/29/2013Gabriel CerroneDirectorBuy12,000$4.09$49,080.00View SEC Filing  
6/21/2013Bernard DenoyerSVPBuy7,500$4.78$35,850.00View SEC Filing  
6/14/2013Gabriel CerroneChairmanBuy8,000$4.42$35,360.00View SEC Filing  
4/24/2013Gabriel CerroneChairmanBuy5,500$4.66$25,630.00View SEC Filing  
2/5/2013Gabriel CerroneChairmanBuy5,000$6.15$30,750.00View SEC Filing  
2/4/2013Gabriel CerroneChairmanBuy13,090$6.04$79,063.60View SEC Filing  
1/30/2013Gabriel CerroneChairmanBuy26,000$5.98$155,480.00View SEC Filing  
11/14/2012Gabriel CerroneChairmanBuy87,820$3.61$317,030.20View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Synergy Pharmaceuticals (NASDAQ:SGYP)
DateHeadline
News IconSynergy Pharmaceuticals, Inc. (SGYP) Set to Announce Quarterly Earnings on Thursday (NASDAQ:SGYP)
mundoaguaysaneamiento.net - February 23 at 7:56 PM
blogs.barrons.com logoDid 50 Salespeople Leave Valeant? Wells Fargo Investigates (NASDAQ:SGYP)
blogs.barrons.com - February 23 at 7:56 PM
News IconThe Charts For Synergy Pharmaceuticals Inc. (SGYP) Is Speaking Volumes Today - NY Stock News (NASDAQ:SGYP)
nystocknews.com - February 22 at 8:00 PM
News Icon86 institutional investors are raising stakes in Synergy Pharmaceuticals Inc. (SGYP) - Post Analyst (NASDAQ:SGYP)
postanalyst.com - February 22 at 8:00 PM
News IconThe Technical Charts For Synergy Pharmaceuticals Inc. (SGYP) Say It All Today - NY Stock News (NASDAQ:SGYP)
nystocknews.com - February 22 at 8:00 PM
News IconSynergy Pharmaceuticals Inc. (SGYP) Analyst Opinion And Outlook ... - Post Analyst (NASDAQ:SGYP)
postanalyst.com - February 20 at 8:57 AM
News IconSynergy Pharmaceuticals Inc SGYP Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NASDAQ:SGYP)
www.bioportfolio.com - February 17 at 7:37 PM
News IconKohl's Corp. (NYSE:KSS), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) (NASDAQ:SGYP)
hypelee.com - February 16 at 7:29 PM
News IconKohl's Corp. (NYSE:KSS), Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) (NASDAQ:SGYP)
hypelee.com - February 16 at 7:29 PM
biz.yahoo.com logoSYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:SGYP)
biz.yahoo.com - February 16 at 7:29 PM
biz.yahoo.com logoSYNERGY PHARMACEUTICALS, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits (NASDAQ:SGYP)
biz.yahoo.com - February 16 at 7:29 PM
News IconQuick Review on Trend Indicator Levels: Synergy Pharmaceuticals Inc. (SGYP) - BVN (NASDAQ:SGYP)
bvnewsjournal.com - February 15 at 5:16 AM
News IconImpact of Brokerage Rating on Synergy Pharmaceuticals, Inc.(SGYP) - Highland Mirror (NASDAQ:SGYP)
www.highlandmirror.com - February 15 at 5:16 AM
News IconSynergy Pharmaceuticals Inc. (SGYP): How technical indicators have come out? - Post Analyst (NASDAQ:SGYP)
postanalyst.com - February 13 at 8:20 AM
seekingalpha.com logoSynergy Pharmaceuticals: Our Next Investment - Seeking Alpha (NASDAQ:SGYP)
seekingalpha.com - February 10 at 3:16 AM
us.rd.yahoo.com logoSynergy Pharmaceuticals to Present at Leerink Partners 6th Annual Global Healthcare Conference (NASDAQ:SGYP)
us.rd.yahoo.com - February 9 at 3:25 AM
marketexclusive.com logoSynergy Pharmaceuticals Inc. (NASDAQ:SGYP) Files An 8-K Other Events (NASDAQ:SGYP)
marketexclusive.com - February 8 at 6:01 AM
us.rd.yahoo.com logoPivotal Phase 3 Data Results for TRULANCE™ (plecanatide) in the Treatment of Chronic Idiopathic Constipation (CIC) Published in American Journal of Gastroenterology (NASDAQ:SGYP)
us.rd.yahoo.com - February 8 at 6:01 AM
News IconTechnical Roundup On Two Stocks Synergy Pharmaceuticals Inc. (SGYP), Mueller Water Products, Inc. (MWA) - Post Analyst (NASDAQ:SGYP)
postanalyst.com - February 6 at 7:54 PM
investorplace.com logo3 Beaten Biotech Stocks That Are Set to Rebound (NASDAQ:SGYP)
investorplace.com - February 6 at 3:37 PM
istreetwire.com logoStocks To Watch: Groupon, Inc. (GRPN), Synergy Pharmaceuticals Inc. (SGYP), MGIC Investment Corporation (MTG) - iStreetWire (NASDAQ:SGYP)
istreetwire.com - February 6 at 8:29 AM
News IconStock Price of Synergy Pharmaceuticals, Inc. (SGYP) Increases 2.39 ... - Highland Mirror (NASDAQ:SGYP)
www.highlandmirror.com - February 6 at 8:29 AM
insidermonkey.com logoPrice For Synergy Pharmaceuticals Inc (SGYP) Public Offering Announced - Insider Monkey (blog) (NASDAQ:SGYP)
www.insidermonkey.com - February 5 at 8:04 AM
News IconSynergy Pharmaceuticals Inc (NASDAQ:SGYP) Is Cheap Right Now - Insider Financial (NASDAQ:SGYP)
www.insiderfinancial.com - February 4 at 7:51 PM
News IconPrice For Synergy Pharmaceuticals Inc (SGYP) Public Offering Announced (NASDAQ:SGYP)
feedproxy.google.com - February 3 at 7:29 AM
marketexclusive.com logoPrice For Synergy Pharmaceuticals Inc (NASDAQ:SGYP) Public Offering Announced (NASDAQ:SGYP)
marketexclusive.com - February 3 at 4:22 AM
News IconEarnings Forecast Research on Synergy Pharmaceuticals, Inc. (SGYP) (NASDAQ:SGYP)
lasignare.com - February 3 at 4:22 AM
News IconEarnings Forecast Research on Synergy Pharmaceuticals, Inc. (SGYP) - Highland Mirror (NASDAQ:SGYP)
www.highlandmirror.com - February 2 at 1:12 AM
us.rd.yahoo.com logoSynergy Pharmaceuticals Announces Pricing of Public Offering of Common Stock (NASDAQ:SGYP)
us.rd.yahoo.com - February 2 at 1:11 AM
marketwatch.com logoSynergy Pharma stock sinks 12.5% after announcement of common stock offering (NASDAQ:SGYP)
us.rd.yahoo.com - February 2 at 1:11 AM
thestreet.com logoPremarket Biotech Movers: Synergy, Arrowhead, BioCryst (NASDAQ:SGYP)
us.rd.yahoo.com - February 2 at 1:11 AM
thestreet.com logoHow to Trade Hot Stocks Apple, Seadrill, Advanced Micro Devices (NASDAQ:SGYP)
www.thestreet.com - February 2 at 1:11 AM
fool.com logoWhy Synergy Pharmaceuticals Shares Fell 14.6% Today (NASDAQ:SGYP)
www.fool.com - February 2 at 1:11 AM
4-traders.com logoSynergy Pharmaceuticals : Announces Proposed Public Offering of Common Stock (NASDAQ:SGYP)
www.4-traders.com - January 31 at 11:14 PM
rttnews.com logoSynergy Pharmaceuticals Inc. (SGYP) Is Falling After Offering Announcement (NASDAQ:SGYP)
www.rttnews.com - January 31 at 11:14 PM
News IconWhat Next for Synergy Pharmaceuticals Inc (SGYP) Stock After Reaching 52-Week High? (NASDAQ:SGYP)
randolphguide.com - January 31 at 11:14 PM
us.rd.yahoo.com logoSynergy Pharmaceuticals Announces Proposed Public Offering of Common Stock (NASDAQ:SGYP)
us.rd.yahoo.com - January 31 at 11:14 PM
News IconSynergy Pharmaceuticals, Inc. (SGYP) Rating Reiterated by Canaccord Genuity (NASDAQ:SGYP)
itapunta.com - January 31 at 2:32 AM
News IconBrokerages Set Synergy Pharmaceuticals, Inc (NASDAQ:SGYP)
prensariotiretail.com - January 31 at 2:32 AM
News IconShares of Synergy Pharmaceuticals, Inc. (SGYP) Sees Large Outflow of Money (NASDAQ:SGYP)
onemma.net - January 31 at 2:32 AM
News IconSynergy Pharmaceuticals, Inc. (NASDAQ:SGYP) Projected EPS At ... - Stock Observer (NASDAQ:SGYP)
www.thestockobserver.com - January 29 at 8:15 PM
seekingalpha.com logoA Post-Approval Take On Synergy Pharmaceuticals - Seeking Alpha (NASDAQ:SGYP)
seekingalpha.com - January 29 at 8:15 PM
News IconTicker Tracker: Looking at Synergy Pharmaceuticals Inc. (SGYP) - Rives Journal (NASDAQ:SGYP)
rivesjournal.com - January 29 at 8:09 AM
News IconWeekend Blitz: Fitbit Stock, Synergy Pharma (SGYP), STX Stock & Halliburton (HAL) - BNL Finance (press release) (registration) (blog) (NASDAQ:SGYP)
bnlfinance.com - January 29 at 8:09 AM
News IconHow Does the Chart Look for Synergy Pharmaceuticals Inc. (SGYP) ? - The USA Commerce (NASDAQ:SGYP)
theusacommerce.com - January 29 at 8:09 AM
seekingalpha.com logoSynergy's Prospects Are Better Than Recent Price Action Suggests (NASDAQ:SGYP)
seekingalpha.com - January 28 at 6:32 AM
smarteranalyst.com logoSynergy Pharmaceuticals Inc (SGYP): Low-Dose Linzess Unlikely to Pose Threat, Says Rodman & Renshaw (NASDAQ:SGYP)
www.smarteranalyst.com - January 28 at 6:32 AM
News IconTracking Williams %R for Synergy Pharmaceuticals Inc. (SGYP) - Sherwood Daily (NASDAQ:SGYP)
sherwooddaily.com - January 27 at 3:16 AM
News IconStock Seesawing as Volatility Sweeps in on Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) - Wall Street Beacon (NASDAQ:SGYP)
wsbeacon.com - January 27 at 3:16 AM
News IconFDA Approves Trulance From Synergy Pharmaceuticals Inc (SGYP) To Battle With Allergan PLC (AGN) Linzess (NASDAQ:SGYP)
feedproxy.google.com - January 25 at 11:01 AM

Social

What is Synergy Pharmaceuticals' stock symbol?

Synergy Pharmaceuticals trades on the NASDAQ under the ticker symbol "SGYP."

Where is Synergy Pharmaceuticals' stock going? Where will Synergy Pharmaceuticals' stock price be in 2017?

7 equities research analysts have issued 1 year price objectives for Synergy Pharmaceuticals' stock. Their forecasts range from $4.00 to $18.00. On average, they anticipate Synergy Pharmaceuticals' share price to reach $11.50 in the next twelve months.

When will Synergy Pharmaceuticals announce their earnings?

Synergy Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Thursday, February, 23rd 2017.

What are analysts saying about Synergy Pharmaceuticals stock?

Here are some recent quotes from research analysts about Synergy Pharmaceuticals stock:

  • BTIG Research analysts commented, "In sum, we think SGYP's Trulance (plecanatide) which was recently granted FDA approval for the treatment of chronic constipation may have a lower incidence of diarrhea side effect (~5% with plecanatide vs. placebo at ~1%) which could interest physicians and patients."He adds, "Ultimately, we believe Trulance will become a meaningful new product in the GI treatment category with sales potential approaching $500M by 2020. With ~40M Americans suffering from chronic constipation and there being widespread usage of OTC laxatives (which does not adequately treat chronic symptoms in many cases), we believe the opportunity for SGYP's Trulance is significant. While we do think Trulance will ultimately take share from Linzess, we think the real market opportunity will be in expanding the overall Rx treatment market. Ultimately, we think the launch of Trulance will lead to more patients switching from OTC laxatives to Rx treatments." (1/26/2017)
  • According to Zacks Investment Research, "Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York. " (1/26/2017)

  • Rodman & Renshaw analysts commented, "Synergy's flagship product, which we anticipate to be launched later this quarter under the trade name Trulance', was approved for the treatment of chronic idiopathic constipation (CIC) over a week ahead of the original PDUFA date of January 29, 2017. Investors should note that, in addition to the near-term launch of Trulance', Synergy also anticipates filing the supplemental New Drug Application (NDA) for the drug in treatment of constipation-predominant irritable bowel syndrome (IBS-C) later this quarter. Trulance' could win approval in the IBS-C indication by the end of this year, in our view, given a roughly 10-month review period. We note that the drug demonstrated solid efficacy and safety across four robustly-designed Phase 3 trials in CIC and IBS-C. In the wake of the landmark milestone of the Trulance' approval, we reiterate our Buy rating and raise our 12-month price target to $18.00 per share from $17.00 on SGYP." (1/20/2017)

Who owns Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Paulson & CO. Inc. (13.39%), Orbimed Advisors LLC (10.14%), State Street Corp (3.49%), Armistice Capital LLC (0.94%), Kingdon Capital Management L.L.C. (0.87%) and Perceptive Advisors LLC (0.27%). Company insiders that own Synergy Pharmaceuticals stock include Alan Joslyn, Bernard Denoyer, John P Brancaccio and Paulson & Co Inc.

Who sold Synergy Pharmaceuticals stock? Who is selling Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Wall Street Associates, Allianz Asset Management AG, Kingdon Capital Management L.L.C., GRT Capital Partners L.L.C., Thompson Siegel & Walmsley LLC, Metropolitan Life Insurance Co. NY and Ladenburg Thalmann Financial Services Inc.. Company insiders that have sold Synergy Pharmaceuticals stock in the last year include John P Brancaccio and Paulson & Co Inc.

Who bought Synergy Pharmaceuticals stock? Who is buying Synergy Pharmaceuticals stock?

Synergy Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Paulson & CO. Inc., Orbimed Advisors LLC, State Street Corp, Perceptive Advisors LLC, Armistice Capital LLC, Russell Investments Group Ltd., Pacad Investment Ltd. and Oberweis Asset Management Inc..

How do I buy Synergy Pharmaceuticals stock?

Shares of Synergy Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Synergy Pharmaceuticals stock cost?

One share of Synergy Pharmaceuticals stock can currently be purchased for approximately $5.48.

Synergy Pharmaceuticals (NASDAQ:SGYP) Chart for Friday, February, 24, 2017


Institutional Ownership Chart

Institutional Ownership by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Earnings History Chart

Earnings by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Dividend History Chart

Dividend Payments by Quarter for Synergy Pharmaceuticals (NASDAQ:SGYP)

Last Updated on 2/24/2017 by MarketBeat.com Staff